Uncomplicated Urinary Tract Infections
Urinary tract infection (UTI) is the most common bacterial infection caused by various pathogens, but most commonly by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis, and Staphylococcus saprophyticus.
A urinary tract infection can develop in any part of the urinary tract, including the urethra, bladder, ureters, or kidneys. They are classified as either complicated or uncomplicated.
Uncomplicated Urinary Tract Infections Epidemiology Segmentation in the 7MM
- Total Occurrence-specific Cases of Uncomplicated Urinary Tract Infection
- Total Diagnosed Cases of Uncomplicated Urinary Tract Infection
- Total Age-specific Cases of Uncomplicated Urinary Tract Infection
- Total Pathogen-specific Cases of Uncomplicated Urinary Tract Infection
- Total Treated Cases (across lines) of Uncomplicated Urinary Tract Infection
Uncomplicated Urinary Tract Infections Epidemiological Insights Observed in the 7MM
(2021)
- The total incident cases of Uncomplicated Urinary Tract Infections in the 7MM were observed to be approximately 19.6K in the year 2021
Uncomplicated Urinary Tract Infections Market Insight
- The market size of Uncomplicated Urinary Tract Infections in the 7MM was found to be approximately USD 927 million in 2021.
- The market size of the US was the highest, accounting for USD 590 million.
- The market size of EU5 in 2021 was found to be USD 228 million, and that of Japan was found to be USD 110 million in the year 2021.
Uncomplicated Urinary Tract Infections Market Strengths
Recent research and development have focused on drugs with novel mechanisms of action to tackle antibiotic resistance. During the last 20 years, there have been some noteworthy advancements toward the development of a urinary tract infection vaccine and also drugs for antibiotic resistance. For E.g. sulopenem is currently targeting the quinolone non-susceptible pool in the pivotal trials.
Uncomplicated Urinary Tract Infections Market Opportunities
Educational programs and campaigns are needed to increase patient awareness of the potential for developing antibiotic resistance due to antibiotics overuse.
Uncomplicated Urinary Tract Infections Emerging Drugs
The emerging drugs in the Uncomplicated Urinary Tract Infections market are
- GSK2140944 (Gepotidacin)
- Sulopenem Etzadroxil - Probenecid
- Uromune (MV140)
- ExPEC Vaccine (ExPEC10V and ExPEC4V)
- GSK3882347, and many others
Uncomplicated Urinary Tract Infections Key Players
The key players working in the Uncomplicated Urinary Tract Infections market are
- GlaxoSmithKline
- Iterum Therapeutics
- Inmunotek
- Janssen Pharmaceuticals
- Fimbrion Therapeutics, and several others.